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Abstract 
Background: There is evidence that suggests that undernutrition has a detrimental effect on malarial immunity in 
children. The aim of the study was to discover whether nutrient supplementation improved development of malarial 
antibody immunity in children up to 18 months of age.
Methods: The study was conducted with a subset of 432 Malawian children from a randomized controlled trial of 
nutritional supplements. The arms included pre- and postnatal small-quantity lipid-based nutrient supplements for 
both mother and child; prenatal supplementation with iron and folic acid; and pre- and postnatal supplementation 
with multiple micronutrients. Paired plasma samples were collected at 6 and 18 months of age. The levels of antibod-
ies against merozoite surface protein 1 (MSP1 19kD) and MSP2, erythrocyte binding antigen 175 (EBA175), reticu-
locyte binding protein homologue 2A (Rh2A9), schizont extract and variant antigens expressed on the surface of 
infected erythrocytes were measured.
Results: At 18 months of age, 5.4% of children were parasitaemic by microscopy and 49.1% were anaemic. Antibod-
ies to the tested merozoite antigens and schizont extract increased between 6 and 18 months and this increase was 
statistically significant for MSP1, MSP2 and EBA175 (p < 0.0001) whereas IgG to variant surface antigens decreased 
with increasing age (p < 0.0001). However, the supplementation type did not have any impact on the prevalence or 
levels of antibodies at either 6 or 18 months of age to any of the tested malaria antigens in either univariate analysis or 
multivariate analysis after adjusting for covariates.
Conclusions: Pre- and postnatal lipid-based nutrient supplementation did not alter malaria antibody acquisition dur-
ing infancy, compared to prenatal supplementation with iron and folic acid or pre- and postnatal supplementation 
with multiple micronutrients.
Trail registeration Clinicaltrials.gov registration number NCT01239693
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Background
Malaria is one of the leading causes of death in children 
and pregnant women with an estimated 214 million new 
cases and 438,000 deaths worldwide in 2015. The disease 
can be caused by five different species of the genus Plas-
modium, of which Plasmodium falciparum causes the 
highest rates of mortality and morbidity and is particu-
larly prominent in young children of sub-Saharan Africa, 
with an estimated 292,000 deaths in 2015 [1].
In sub-Saharan Africa, malaria and malnutrition often 
co-exist, and both contribute significantly to deaths in 
young children. However, studies of possible synergistic 
clinical effects of malaria and malnutrition have given 
conflicting results, indicating the need for further stud-
ies in this area. For example, in a cross-sectional study 
among pre-school Kenyan children [2] and a longitudi-
nal study in Gambian children under 5 years of age [3], 
stunting was associated with increased malarial risk, 
but in Papua New Guinea it was reported that stunting 
might protect children against clinical malaria episodes 
[4]. Some other studies noted no significant associa-
tion between anthropometric measurements [5], stunt-
ing [6] or undernutrition [7] and altered susceptibility to 
malaria.
A limited number of studies have examined the impact 
of nutrient supplementation on malaria susceptibility in 
children. Zinc and vitamin A supplementation reduced 
clinical malaria episodes caused by P. falciparum in 
young children [8–10]. In a high malaria transmis-
sion setting, iron supplementation was associated with 
increased parasitaemia [11] and increased mortality [12] 
in iron-sufficient children, whereas the provision of iron 
with micronutrients was associated with reduced risk 
of malaria in iron-deficient children [13]. Other stud-
ies have found evidence of associations between acute 
malaria and deficiency of thiamine [14] and antioxidants 
including vitamin E [15], which suggests they have roles 
in protection against malaria. While there is limited evi-
dence that supplementation with micronutrients such as 
zinc or vitamin B12 can improve antibody response to 
vaccination [16, 17], the ability of micro- or macronutri-
ent supplementation to affect the acquisition of antibody 
to pathogens following natural exposure is unknown.
The aim of this study was to identify whether pre- and 
postnatal nutritional supplements could improve malar-
ial immunity in young children. The study was part of 
a nutrient supplementation clinical trial, the Interna-
tional Lipid-based Nutrient Supplement (iLiNS) Project 
DYAD-Malawi trial (clinicaltrials.gov registration num-
ber NCT01239693). For this report, the level and preva-
lence of antibody to merozoite antigens, schizont extract 
and variant surface antigens (VSA) expressed by P. falci-
parum-infected erythrocytes (IEs) were determined in 
infants aged 6 and 18 months as antibodies to merozoite 
antigens and VSAs are believed to play important roles 
in mediating acquired immunity against malaria [18, 19].
Methods
Study location and participants
The study participants were a cohort of 432 infants resid-
ing in Lungwena, Malindi and Mangochi from rural 
Malawi who participated in the iLiNS Project DYAD-
Malawi nutrient supplementation trial, part of the iLiNS 
Project [20]. The details of the trial design and supple-
ments have been published elsewhere [21]. In brief, par-
ticipating pregnant women were randomly allocated to 
receive iron and folic acid (IFA), multiple micronutrients 
(MMN) or a small-quantity (20  g) of lipid based nutri-
ent supplement (LNS) daily. After delivery, women in the 
IFA group received placebo tablets, while MMN and LNS 
supplementation was continued during the first 6 months 
of lactation. Children of mothers in the LNS group also 
received LNS 10  g twice daily from 6 to 18  months of 
age. At 18  months of age, anthropometric assessments 
revealed no significant differences in the children’s mean 
length, mean weight, the prevalence of stunting, or head 
or mid-upper arm circumference between the interven-
tion groups for all participants in the iLiNS project [22]. 
Plasma samples were collected from infants at 6 and 
18  months of age. At these time points blood haemo-
globin concentration was measured with a Hemo-Cue® 
haemoglobinometer from venous blood samples. Malaria 
parasitaemia was sought by microscopic examination of 
thick blood film and by rapid diagnostic test (RDT) using 
 Clearview® Malaria Combo (British Biocell International 
Ltd., Dundee, UK).
Plasma samples preparation
Blood from participants was separated by centrifugation 
shortly after collection and plasma was stored at − 80 °C 
before shipment on dry ice to Australia. Plasma samples 
were heat-inactivated for 45  min at 57  °C to inactivate 
complement proteins. The heat-inactivated samples were 
then stored at − 80 °C.
Culturing and maintaining parasites
The P. falciparum lines used were E8B-ICAM, R29 and 
3D7 varA over-expressing parasite line. E8B-ICAM 
adheres to ICAM-1 and CD36 [23], and expresses group 
B/C var genes whereas R29 expresses group A var genes 
and forms rosettes [24]. The 3D7 line spontaneously 
expressed a group A var gene as its dominant transcript 
[25]; its binding ligands have not been characterized. 
The parasites were grown and maintained in culture as 
described previously [26]. IEs were synchronized with 
5% sorbitol and subject to gelatin flotation regularly [27]. 
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To select R29 for rosetting, gelatin flotation without then 
with heparin lithium salt, 0.05  mg/ml Sigma Aldrich), 
was performed.
Measuring IgG to malaria merozoite antigens and schizont 
extract
Recombinant merozoite protein 1 (MSP-1 19 kD, 3D7 
clone), region III-V of erythrocyte binding antigen 175 
(EBA 175), and P. falciparum reticulocyte binding hom-
ologue 2 (PfRh2, construct PfRh2-2030) were expressed 
in Escherichia coli as previously reported [28–30]. Full-
length MSP-2 (FC27 clone) expressed in E. coli was 
kindly provided by Robin Anders (La Trobe University, 
Australia). The schizont extract was prepared according 
to a previously published method [31]. Briefly, magnetic-
activated cell sorting (MACS) purified schizont pellet was 
mixed with three times the volume of the pellet with PBS. 
Cell-lysis was done by freeze-thawing for 6 times, then it 
was spun down to clarify the supernatant and this extract 
was used after optimizing the coating concentration.
Each merozoite antigen was coated at 0.5–2  µg/ml 
and schizont extract at 1:8000 dilution on to 384 well 
NUNC MaxiSorp™ plates (Thermo Fisher Scientific Inc, 
MA, USA) and left overnight at 4  °C. The plates were 
washed with PBS/Tween 20 and non-specific binding was 
blocked with 0.1% casein (Thermo Fisher Scientific) on 
the following day. The plates were then incubated with 
participant sera diluted at 1:250 in 0.1% casein in tripli-
cates for 1 h and washed. Horseradish peroxidase-conju-
gated goat anti-human IgG (Life Technologies, Australia) 
was added at 1:2500 dilution for 1 h and plates were again 
washed. ABTS [2,2′-azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid)] was added as enzyme–substrate for 
15  min and absorbance at 405  nm was measured using 
a BMG POLARstar Omega fluorimeter (BMG Labtech, 
Germany).
Measurement of total IgG levels against VSA
Total IgG antibody levels against VSAs expressed on the 
surface of IEs were measured by flow cytometry as pre-
viously described [32] with slight modifications. These 
antibodies are believed to primarily target P. falciparum 
erythrocyte membrane antigen 1 (PfEMP1) [33]. In brief, 
2.5  μl of patient sera (1:20 dilution) were co-incubated 
with IEs at 0.2% haematocrit and at approximately 7–8% 
parasitaemia, diluted in PBS solution with 1% HI-FBS 
(Heat inactivated fetal bovine serum) for 30  min. Fol-
lowing incubation the cells were washed 3 times with 
PBS/1% HI-FBS and incubated with 25  μl of 1:100 rab-
bit anti-human IgG (Dako, Australia) diluted in PBS/1% 
HI-FBS. The cells were washed again in PBS/1% HI-FBS 
and incubated with Alexa Fluor 647 donkey anti-rabbit 
IgG in 1:500 dilution (Life Technologies, Australia) and 
10  μg/ml ethidium bromide (EtBr) in PBS/1% HI-FBS 
for 30  min. Following incubation the cells were washed 
in PBS/1% HI-FBS and resuspended in ice-cold 2% para-
formaldehyde fixative solution (prepared in PBS). The 
fixed IEs were then run through a  HyperCyt® system 
with a plate reader adapter  (Intellicyt®, NM, USA) con-
nected to a Cyan flow cytometer (Beckman Coulter 
Inc., CA, USA) where the cells were acquired. The flow 
cytometry data was analysed according to a previously 
published method [32].
Data analysis
Statistical analyses were performed using Stata version 
13.0 (StataCorp, Texas, USA). Statistical analyses were 
performed according to a pre-planned and approved 
analysis plan available at [34]. Measured antibody levels 
(in optical density [OD] for schizont and merozoite anti-
gens and geometric mean fluorescence intensity [MFI] 
for VSA) were presented as a percentage of the positive 
control. The positive control came from a pool of plasma 
from malaria immune African adults whereas the nega-
tive control came from plasma samples from 3 Mel-
bourne donors for the ELISA and 8 Melbourne donors 
for the flow cytometry assay.
Seroprevalence was defined as the percentage of the 
cohort having antibody responses greater than the mean 
antibody response plus three standard deviations for neg-
ative controls, which were malaria naïve samples from 
Melbourne blood donors. Socioeconomic status (SES) 
was calculated on the basis of a scoring system for house-
hold assets (HHA) adapted from [35].
Participant characteristics including demographic and 
basic clinical characteristics were categorized by inter-
vention groups and the median and interquartile range 
for each characteristic were tabulated. Differences in 
characteristics across the groups were determined by 
Mann–Whitney test (non-parametric continuous vari-
ables with two groups), Kruskal–Wallis (non-parametric 
continuous variables with more than two groups) or  Chi2 
test (for categorical variables) where applicable. Differ-
ences in the antibody level and the seropositivity between 
6 and 18 months old children were determined by Wil-
coxon matched-pairs signed-ranks test and McNemar’s 
test, respectively. Statistical differences between the 
groups were reported as p  <  0.05 and 95% confidence 
intervals were also reported for the analyses.
Antibody levels at 6 and 18  months of age were 
reported as the median percentage of the positive con-
trol and the interquartile range (IQR). The Kruskal–Wal-
lis test was performed to compare antibody levels across 
supplementation groups. Regression analyses were car-
ried out using natural logarithmically transformed anti-
body levels which were back transformed for reporting 
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descriptive results. Linear regression univariate analysis 
was performed between LNS versus IFA, LNS versus 
MMN and MMN versus IFA to determine the antibody 
level differences between supplementation groups. Mul-
tivariate regression was also performed adjusting for the 
following covariates: maternal BMI at enrolment, dura-
tion of gestation (from enrolment to delivery), number of 
pregnancies, sex of the child, maternal education, proxy 
for SES, study site, maternal anaemic status at enrol-
ment, maternal HIV status and bed net use by children 
and these covariates were uniformly included in all the 
adjusted analyses according to the pre-specified analysis 
plan. For both univariate and multivariate analyses, coef-
ficients and 95% confidence intervals (CI) were reported. 
The number and the percentage of children who were 
seropositive for each malaria antigen were reported by 
supplementation groups, and  chi2 test was performed 
to determine the differences across the supplementation 
groups. Univariate logistic regression was performed 
between LNS versus IFA, LNS versus MMN and MMN 
versus IFA to determine the differences in seropositivity 
between different supplementation groups. Multivari-
ate logistic regression was performed adjusting for the 
above-mentioned covariates, reporting odds ratios (OR) 
and 95% CI.
Results
Study population characteristics
From a total of 1391 enrolled pregnant women recruited 
to the trial, 869 completed the intervention and follow-
up to 18 months after delivery. Four hundred and thirty-
two singleton children from these women with sample 
availability at both 6 and 18 months were tested for this 
study (Fig. 1).
Of the 432 children (47.9% male and 52.1% female) 
tested at 6 and 18 months of age, 33.6% were from the IFA 
group, 32.4% from the MMN group and 34.0% in the LNS 
group. Table 1 summarizes the participant characteristics 
Fig. 1 Participant flow in Consolidated Standards of Reporting Trials recommended format; adapted and modified from [22]. gest gestation, IFA iron 
and folic acid, LNS lipid-based nutrient supplement, MMN multiple micronutrients
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according to different supplementation groups. The char-
acteristics did not differ substantially between the three 
intervention groups. The percentages of children who 
were parasitaemic at 6  months were higher in children 
from the IFA group (8.3% by microscopy and 7.6% by 
RDT) compared to MMN (3.6% by microscopy and 7.1% 
by RDT) or LNS (3.4% by microscopy and 6.8% by RDT) 
but the differences were non-significant.
The characteristics of the included and excluded chil-
dren at 6 months are illustrated in Table 2. Significantly 
more included children had parasitaemia by microscopy 
(P = 0.01), but results of RDT showed no such difference. 
The percentage of anaemia at 6 months was significantly 
higher (P < 0.0001) in the excluded participants (71.7%) 
than the included group (58.1%).
The magnitude and prevalence of antibodies in different 
age groups
The levels of antibodies and seroprevalence for the anti-
bodies against merozoite antigens, schizont extract and 
VSA for three different parasite lines were measured at 
6 months and 18 months of age (Table 3). The antibody 
levels to the merozoite antigens and schizont extract 
were significantly higher at 18  months compared to 
the levels at 6 months and it was statistically significant 
(P < 0.0001) for MSP1, MSP2 and EBA175.
However, the levels of naturally acquired IgG against 
VSAs were significantly lower in children at 18 months of 
age compared to the same children at 6 months. This dif-
ference was significant (< 0.0001) for all the tested para-
site lines.
As with the antibody level data, seroprevalence of anti-
bodies against the tested merozoite antigens and schizont 
extract were also significantly higher at 18  months com-
pared to the seroprevalence at 6 months. The highest per-
centage of seropositivity was observed against MSP1 in 
Table 1 Participant characteristics according to supplementation groups
a Iron and folic acid supplementation
b Multiple micronutrient supplementation
c Lipid-based nutrient supplements
d P value obtained by Kruskal–Wallis test (continuous variables) or Chi square test
e Rapid diagnostic test
f Anaemia defined as haemoglobin level < 110 g/l (World Health Organization [1])
Characteristics IFAa
n (%)
MMNb
n (%)
LNSc
n (%)
P  valued
Number of children 145
(33.6)
140
(32.4)
147
(34.0)
0.87
Male 69
(47.6)
61
(43.6)
77
(52.4)
0.32
Parasitaemia by microscopy at 6 months 12
(8.3)
5
(3.6)
5
(3.4)
0.10
Parasitaemia by  RDTe at 6 months 11
(7.6)
10
(7.1)
10
(6.8)
0.97
Haemoglobin level at 6 months, mean ± SD, g/l 102.7 ± 16.7 103.6 ± 16.0 103.7 ± 14.7 0.74
Anaemiaf at 6 months 86
(59.3)
81
(57.9)
84
(57.1)
0.93
Low socioeconomic status 95
(65.5)
75
(53.6)
81
(55.1)
0.08
Mother’s education below median 79
(54.5)
66
(47.1)
80
(54.4)
0.34
Table 2 Comparative characteristics of the included 
and excluded participants at 6 months of age
Values are number (%) or mean ± SD
a P value obtained by Chi square test or Mann–Whitney test (continuous 
variables)
b Rapid diagnostic test
c Anaemia defined as haemoglobin level < 110 g/l (World Health Organization 
[1])
Characteristics Included (432) Excluded (349) P  valuea
Parasitaemia by micros-
copy
22 (5.1) 6 (1.7) 0.01
Parasitaemia by  RDTb 31 (7.17) 35 (10.0) 0.15
Haemoglobin level, 
mean ± SD, g/l
103.4 ± 15.8 101.4 ± 15.9 0.09
Anaemiac 251 (58.1) 250 (71.7) < 0.0001
Low socioeconomic status 251 (58.1) 215
(61.6)
0.32
Mother’s education below 
median
225 (52.1) 193 (55.3) 0.37
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18 month old children; 54.6% compared to 29.6% seroposi-
tives at 6 months (P < 0.0001). Significant increases in sero-
positivity with increasing age were also observed for Rh2A9 
(P  <  0.0001) and schizont extract (P =  0.0314). However, 
the seroprevalence of IgG against VSAs of different parasite 
lines declined significantly between 6 and 18 months of age 
for the three tested parasite lines (P < 0.0001 for IgG against 
E8B and 3D7 and P = 0.0016 for R29).
Association between nutrient supplementation 
and antibody seroprevalence in 6 months old children
Seroprevalence of the malaria antigens in 6  months old 
children was not significantly different between any of 
the treatment arms for any of the tested antigens except 
Rh2A9 (P = 0.044) (Table 4). Adjustment of the analysis 
for the selected covariates did not significantly change the 
results of the analysis, and the only significant difference 
was observed for the odds ratio of Rh2A9 between LNS 
and IFA group in the univariate analysis (P = 0.047), with 
the odds of being seropositive at 6 months of age in LNS 
group being 54% less than in the IFA group. This associa-
tion did not remain significant in the adjusted analysis.
Association between nutrient supplementation 
and antibody seroprevalence in 18 months old children
Seroprevalence of the tested malaria antigens in 
18  months old children was not significantly different 
between any of the treatment arms for any of the anti-
gens tested (Table  5). Adjustment of the analysis for 
the selected covariates did not significantly change the 
results of the analysis, and no significant differences in 
antibody seroprevalence were observed between the dif-
ferent supplementation groups for any of tested antigens.
Association between nutrient supplementation 
and antibody levels in 6 month old children
The level of antibodies did not differ significantly accord-
ing to different nutrient supplementation groups for any 
of the tested antigens at 6 months of age. Moreover, mul-
tivariate linear regression showed no significant differ-
ences in the levels of antibodies against any of the tested 
antigens when they were categorized by different supple-
mentation groups (Table 6).
Association between nutrient supplementation 
and antibody levels in 18 month old children
The level of antibodies did not differ significantly between 
different nutrient supplementation groups for any of the 
tested antigens except for IgG against E8B parasite line 
(P = 0.043) in 18 months old children. Multivariate linear 
regression showed no significant differences in the levels 
of antibodies against any of the tested antigens between 
the different supplementation groups (Table 7).
Discussion
This study investigated the impact of nutritional sup-
plementation on malarial immunity in a subset of young 
children from a randomized controlled trial of pre-natal 
Table 3 Magnitude and prevalence of antibodies in 432 children at 6 and 18 months
a Plasmodium falciparum
b Antibody level presented as a percentage of the positive control showing the median and interquartile range
c Seropositivity defined as sample mean optical density or fluorescence intensity > mean + 3 standard deviations of the negative controls
d P value calculated using Wilcoxon matched-pairs signed-ranks test
e P value calculated using McNemar’s test
f Merozoite surface protein 1
g Merozoite surface protein 2
h Erythrocyte binding antigen 175
i Reticulocyte binding protein homologue 2A
Significant P values <0.05 are indicated in italics
Antigen tested/Pfa isolate Antibody  levelb P  valued Antibody  seropositivityc (%) P  valuee
6 months 18 months 6 months 18 months
MSP1f 0.97 [0.38, 2.89] 2.80 [0.83, 6.35] < 0.0001 128 (29.6) 236 (54.6) < 0.0001
MSP2g 2.14 [1.31, 3.59] 2.95 [0.92, 9.12] < 0.0001 114 (26.3) 117 (27.0) 0.1004
EBA175h 2.50 [1.44, 4.13] 3.73 [2.19, 18.73] < 0.0001 48 (11.1) 51 (11.8) 0.5764
Rh2A9i 5.49 [2.01, 33.78] 8.5 [4.68, 14.29] 0.2829 14 (3.2) 122 (28.2) < 0.0001
Schizont 1.92 [0.84, 6.99] 3.32 [1.44, 6.89] 0.2522 202 (46.7) 233 (53.9) 0.0314
E8B 0.20 [0.03, 0.45] 0 [0, 0.21] < 0.0001 105 (25.2) 34 (7.8) < 0.0001
R29 0.18 [0, 0.63] 0 [0, 0.11] < 0.0001 37 (9.1) 16 (3.7) 0.0016
3D7 0.23 [0.01, 0.53] 0 [0, 0.29] < 0.0001 94 (22.2) 36 (8.3) < 0.0001
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nutrient supplementation with IFA or pre- and postnatal 
MMN or LNS. Antibodies to several important merozoite 
antigens (MSP1, MSP2, EBA175, Rh2A9), schizont extract 
and VSA for three different parasite lines (E8B-ICAM, R29 
and 3D7 overexpressing var A) were measured in order to 
determine whether nutrient supplementation improves 
the acquisition of malaria antibody in young children.
In malaria endemic areas, antibodies to malaria anti-
gens increase with age, being higher in adults than in 
children, but the dynamics of antibody production in 
infants are less well studied [36]. The observations that 
the levels and seroprevalence of antibody to most of 
the merozoite antigens tested increased between 6 and 
18 months of age are in agreement with observations in 
a case control study conducted in Kenyan children, in 
which the level of antibodies against MSP1 and PfRh2 
increased steadily with increasing age from birth to 
2 years [37], and a cohort study from Benin [38], in which 
MSP1 and MSP2 antibody levels showed a constant 
increase until 18 months of age. In a higher transmission 
Table 4 Association between nutrient supplementation and seroprevalence in 6 months old children
a Iron and folic acid
b Multiple micronutrients
c lipid based nutrient supplements
d  P value calculated using the  Chi2 test
e  P value calculated using logistic regression reporting Odds Ratios (OR) and 95% Confidence intervals (CI)
f Merozoite surface protein 1
g P value calculated using multivariate logistic regression reporting odds ratios (OR) while adjusting for maternal BMI at enrolment, duration of gestation (from 
enrolment to delivery), number of pregnancies, sex of the child, maternal education, socioeconomic status, study site, maternal anaemic status at enrolment, maternal 
HIV status and bed net use by children
h Merozoite surface protein 2
i Erythrocyte binding antigen 175
j Reticulocyte binding protein homologue 2A
k Variant surface antigens
Significant P values <0.05 are indicated in italics
Outcome Number of children seropositive/
total number of children
Comparison 
between LNS and IFA 
group
Comparison 
between LNS and MMN 
group
Comparison 
between MMN and IFA 
group
IFAa MMNb LNSc P  valued OR (95% CI) P  valuee OR (95% CI) P  valuee OR (95% CI) P  valuee
MSP-1f 19kD 43/145
(29.7%)
44/140
(31.4%)
41/147
(27.9%)
0.806 0.96 (0.74, 1.23) 0.739 0.84 (0.51, 1.40) 0.512 1.07 (0.64, 1.77) 0.804
Adjusted  modelg 0.97 (0.73, 1.28) 0.808 0.86 (0.49, 1.49) 0.583 1.01 (0.57, 1.76) 0.981
MSP-2h 38/145
(26.2%)
40/140
(28.6%)
36/147
(24.5%)
0.734 0.96 (0.73, 1.24) 0.736 0.81 (0.48, 1.37) 0.434 1.07 (0.63, 1.80) 0.807
Adjusted  modelg 0.98 (0.74, 1.31) 0.893 0.80 (0.45, 1.42) 0.447 1.09 (0.62, 1.94) 0.764
EBA-175i 15/145
(10.3%)
20/140
(14.3%)
13/147
(8.9%)
0.320 0.92 (0.62, 1.35) 0.663 0.58 (0.28, 1.22) 0.152 1.34 (0.65, 2.76) 0.426
Adjusted  modelg 0.96 (0.63, 1.47) 0.857 0.54 (0.25, 1.18) 0.120 1.53 (0.70, 3.37) 0.289
Rh2A9j 9/145
(6.21%)
3/140
(2.14%)
2/147
(1.4%)
0.044 0.46 (0.21, 0.99) 0.047 0.63 (0.10, 3.83) 0.616 0.33 (0.09, 1.23) 0.098
Adjusted  modelg 0.48 (0.21, 1.06) 0.070 0.79 (0.12, 5.42) 0.814 0.34 (0.09, 1.30) 0.114
Schizont extract 68/145
(46.9%)
67/140
(47.86%)
67/147
(45.6%)
0.927 0.97 (0.77, 1.23) 0.821 0.91 (0.57, 1.45) 0.699 1.07 (0.67, 1.71) 0.774
Adjusted  modelg 0.91 (0.70, 1.18) 0.468 0.89 (0.53, 1.51) 0.677 0.97 (0.58, 1.63) 0.923
VSAk of E8B parasite line 31/145
(21.4%)
39/140
(27.9%)
35/147
(23.8%)
0.437 1.09 (0.83, 1.43) 0.552 0.80 (0.47, 1.36) 0.402 1.52 (0.88, 2.64) 0.134
Adjusted  modelg 1.01 (0.74, 1.37) 0.957 0.70 (0.38, 1.26) 0.233 1.55 (0.86, 2.80) 0.146
VSA of R29 parasite line 14/145
(9.7%)
12/140
(8.6%)
11/147
(7.5%)
0.803 0.86 (0.57, 1.30) 0.470 0.83 (0.35, 1.94) 0.659 0.88 (0.39, 1.98) 0.756
Adjusted  modelg 0.76 (0.48, 1.20) 0.234 0.69 (0.27, 1.74) 0.427 0.91 (0.38, 2.14) 0.822
VSA of 3D7 parasite line 27/145
(18.6%)
33/140
(23.6%)
34/147
(23.1%)
0.530 1.16 (0.87, 1.54) 0.313 0.97 (0.56, 1.69) 0.924 1.35 (0.76, 2.41) 0.301
Adjusted  modelg 1.04 (0.75, 1.43) 0.829 0.89 (0.48, 1.65) 0.721 1.24 (0.66, 2.31) 0.501
Page 8 of 13Barua et al. Malar J  (2018) 17:74 
setting, the seroprevalence of antibody to MSP1 reached 
a peak after 6 months of age, whereas prevalence of anti-
body to MSP2 peaked at 9 months of age [39].
In contrast to the increase in antibodies to merozoite 
antigens, the levels of antibodies against VSA decreased 
from 6 to 18  months, suggesting an ongoing loss of 
maternal anti-VSA antibodies with little or no develop-
ment of the child’s own VSA antibody responses. Con-
sistent with this, in a recent study anti-VSA antibodies 
waned by 6–9 months of age and did not reappear dur-
ing infancy and early childhood [40]. It is possible that 
the anti-VSA antibodies require more infections than the 
merozoite antigens to develop, and anti-VSA responses 
are known to often be short-lived following infection 
[41]. This may be related to the highly variant nature of 
VSA [42], requiring repeated exposure to develop cross-
reactive antibodies to multiple VSA variants, whereas 
merozoite antigens are more conserved.
The study found no evidence that nutrient supplemen-
tation altered the development of antibody responses to 
either merozoite antigens or VSA in young children, in 
accordance with a study conducted on Beninese children 
Table 5 Association between nutrient supplementation and seroprevalence in 18 months old children
a Iron and folic acid
b Multiple micronutrients
c lipid based nutrient supplements
d  P-value calculated using the  Chi2 test
e  P-value calculated using logistic regression reporting Odds Ratios (OR) and 95% Confidence intervals (CI)
f Merozoite surface protein 1
g P-value calculated using multivariate logistic regression reporting odds ratios (OR) while adjusting for maternal BMI at enrolment, duration of gestation (from 
enrolment to delivery), number of pregnancies, sex of the child, maternal education, socioeconomic status, study site, maternal anaemic status at enrolment, maternal 
HIV status and bed net use by children
h Merozoite surface protein 2
i Erythrocyte binding antigen 175
j Reticulocyte binding protein homologue 2A
k Variant surface antigens
Outcome Number of children seropositive/
total number of children
Comparison 
between LNS and IFA 
group
Comparison 
between LNS and MMN 
group
Comparison 
between MMN and IFA 
group
IFAa MMNb LNSc P  valued OR (95% CI) P  valuee OR (95% CI) P  valuee OR (95% CI) P  valuee
MSP-1  19kDf 82/145
(56.5%)
72/140
(51.4%)
82/147
(55.7%)
0.646 0.98 (0.78, 1.24) 0.895 1.19 (0.75, 1.90) 0.460 0.83 (0.52, 1.33) 0.444
Adjusted  modelg 0.98 (0.77, 1.25) 0.865 1.10 (0.67, 1.82) 0.708 0.80 (0.48, 1.34) 0.398
MSP-2h 42/145
(28.9%)
39/140
(27.8%)
36/147
(24.4%)
0.669 0.88 (0.66, 1.16) 0.359 0.79 (0.45, 1.40) 0.428 0.95 (0.54, 1.66) 0.851
Adjusted  modelg 0.82 (0.60, 1.13) 0.226 0.63 (0.34, 1.18) 0.149 0.96 (0.53, 1.76) 0.906
EBA-175i 19/145
(13.1%)
14/140
(10.0%)
18/147
(12.2%)
0.705 0.99 (0.67, 1.43) 0.967 1.59 (0.69, 3.63) 0.273 0.61 (0.27, 1.40) 0.242
Adjusted  modelg 0.91 (0.60, 1.37) 0.642 1.19 (0.48, 2.95) 0.710 0.65 (0.27, 1.58) 0.342
Rh2A9j 42/145
(28.9%)
40/140
(28.5%)
40/147
(27.2%)
0.941 0.96 (0.74, 1.24) 0.739 0.93 (0.56, 1.57) 0.797 0.96 (0.57, 1.61) 0.880
Adjusted  modelg 0.96 (0.73, 1.26) 0.763 0.84 (0.48, 1.47) 0.540 0.98 (0.56, 1.71) 0.931
Schizont extract 73/145
(50.3%)
78/140
(55.7%)
82/147
(55.7%)
0.568 1.12 (0.89, 1.40) 0.352 1.003 (0.63, 1.60) 0.991 1.24 (0.78, 1.99) 0.365
Adjusted  modelg 1.18 (0.90, 1.54) 0.223 0.87 (0.52, 1.46) 0.600 1.40 (0.83, 2.35) 0.208
VSAk of E8B parasite line 14/145
(9.6%)
11/140
(7.9%)
9/147
(6.1%)
0.534 0.78 (0.51, 1.21) 0.266 0.76 (0.30, 1.89) 0.554 0.78 (0.33, 1.83) 0.562
Adjusted  modelg 0.80 (0.50, 1.29) 0.360 0.72 (0.27, 1.89) 0.504 0.75 (0.29, 1.93) 0.557
VSA of R29 parasite line 7/145
(4.8%)
5/140
(3.5%)
4/147
(2.7%)
0.632 0.74 (0.40, 1.39) 0.351 0.76
(0.20, 2.87)
0.680 0.72 (0.22, 2.32) 0.582
Adjusted  modelg 0.79 (0.39, 1.60) 0.506 0.95 (0.22, 4.07) 0.946 0.85 (0.23, 3.14) 0.808
VSA of 3D7 parasite line 15/145
(10.3%)
11/140
(7.8%)
10/147
(6.8%)
0.532 0.80 (0.52, 1.21) 0.283 0.86 (0.35, 2.08) 0.732 0.85 (0.37, 1.97) 0.710
Adjusted  modelg 0.74 (0.46, 1.22) 0.241 0.55 (0.20, 1.52) 0.250 1.11(0.43, 2.83) 0.830
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of similar age group in whom there was no association 
between nutritional intake and anti-malarial antibody 
levels [38]. Antibody levels or seroprevalence of anti-
bodies to the tested antigens did not differ between the 
supplementation groups in either unadjusted or adjusted 
analysis (P  >  0.05) except for the seroprevalence in 
6  months old children for Rh2A9 (P =  0.044), and that 
significance was lost in the adjusted analysis. The trial 
did not demonstrate differences in growth or morbidity 
events between the different supplementation arms and 
suggested that the nutritional supplements provided were 
not sufficient by themselves to promote infant growth 
[22]. This may also explain why no differences were seen 
in anti-malaria antibody levels between the intervention 
groups.
Clinical studies have suggested that under-nutrition 
has an impact on early childhood mortality and morbid-
ity [2, 43]. However, other studies did not find any rela-
tionship between protein energy malnutrition or stunting 
and clinical malaria occurrence [7, 44]. The interaction 
between nutrition and malarial immunity has been rela-
tively little studied. Among Senegalese pre-school chil-
dren, those children who were stunted had lower levels 
of IgG to schizont extract compared to non-stunted chil-
dren [45], and Papua New Guinean children with wast-
ing were reported to have lower levels of specific IgG 
to blood stage malaria antigens [4]. But these previous 
studies of the impact of nutritional status on malarial 
immunity were observational and therefore subjected to 
confounding. The only statistically significant difference 
between the supplement groups seen in the present study 
in 6 months old children was the seroprevalence against 
Rh2A9 between three treatment arms (P  =  0.044); the 
univariate analysis also showed significant differences in 
the odds ratio between LNS and IFA group. There was no 
significant association in the adjusted analysis. Although 
IgG against VSA in E8B parasite line in 18  months old 
children was significantly different in unadjusted analy-
ses between groups (P =  0.043), this, together with the 
Rh2A9 observations, were most probably chance find-
ings, in the absence of similar findings in other assays.
Strengths of the study include the substantial sample 
size of children from a randomized controlled trial with 
paired samples at 6 and 18 months of age and the number 
of different antibody measurements performed. A high 
proportion of iLiNS study participants were stunted at 
18 months of age, indicating a high prevalence of nutri-
tional deprivation, frequent infection or inflammation in 
infants. Possible study weaknesses include the relatively 
low prevalence of severe nutritional deficits in the moth-
ers [21] as a previous study showed that with protein 
energy supplementation, improved birth outcome was 
more prominently observed in malnourished mothers 
than marginally nourished or well-nourished mothers 
[46]. Other limitations could be the inclusion of only a 
subset of all children followed in the parent study [21], 
the potential selection bias due to differences in the 
included and excluded children, different assay platforms 
for measuring merozoite immunity (ELISA) compared 
to VSA immunity (flow cytometry), and the lack of func-
tional assays of malaria immunity [36].
Conclusions
In conclusion, this study reports the acquisition of 
malaria antibody in young children with different pre- 
and postnatal nutrient supplements and shows no 
significant changes in antibody acquisition among dif-
ferent supplement groups. It addresses the knowledge 
gap regarding the effect of nutrient supplementation on 
malarial immunity in young children. Further studies 
may be required to determine whether malaria immunity 
is significantly impaired in groups with severe nutritional 
depletion, or whether more substantial protein energy 
supplementation might help the development of malaria 
immunity, especially in high risk groups.
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